Amati Global Investors

Manufacture 2030 is a digital platform focused on reducing resource consumption in global manufacturing with the goal of achieving significant sustainability by 2030. The company has developed a cloud-based tool named M2030 bee, which assists manufacturers in increasing profitability by lowering operational costs and minimizing environmental impacts. This platform provides essential data and tools to help suppliers measure, manage, and reduce their greenhouse gas emissions, thereby enabling clients to meet emissions reduction targets. Through its innovative approach, Manufacture 2030 aims to enhance the efficiency and sustainability of manufacturing supply chains while fostering a more responsible industry.

Flylogix specializes in the development of advanced unmanned aircraft designed for efficient operations in remote environments. The company offers full-service over-horizon capabilities that enable the delivery of essential business information from challenging locations. Its range of services includes maritime surveillance, oil spill response, airspace management, methane emissions monitoring, and unmanned logistics. By leveraging these technologies, Flylogix aids organizations in transforming their remote operations, reducing carbon emissions, enhancing safety, and implementing cost-effective solutions.

eleXsys Energy operates as a cleantech energy company. eleXsys Energy’s innovative technology unlocks the full potential of electricity networks, by providing services that enable a two way flow of electricity on grids

eleXsys Energy operates as a cleantech energy company. eleXsys Energy’s innovative technology unlocks the full potential of electricity networks, by providing services that enable a two way flow of electricity on grids

Amryt Pharma is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for patients with serious and life-threatening rare diseases. Founded in 2015 and based in London, the company offers several commercial products, including Myalept, which treats complications related to leptin deficiency in patients with generalized lipodystrophy, and Lojuxta, a medication for adults with homozygous familial hypercholesterolemia. Amryt Pharma is also advancing its research pipeline, including FILSUVEZ, aimed at treating the skin manifestations of epidermolysis bullosa, and AP103, a pre-clinical gene therapy for recessive dystrophic epidermolysis bullosa. The company markets its products across the Americas, Europe, and the Middle East, focusing on addressing high unmet medical needs in rare and orphan diseases.